Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn
Ella Day | June 25, 2025 | Appointment | Research and Development | CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution
Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former chairman and CEO of Fresenius Medical Care; and Mark Hahn, chief financial officer (CFO) of Verona Pharma. The appointments mark a strategic milestone as the company prepares for clinical trials of its non-glucose based peritoneal dialysis (PD) solution.
Powell brings over 30 years of leadership in global renal care, having led Fresenius Medical Care – one of the world’s largest dialysis product and service providers – through a decade of international expansion. Powell said: “Opterion Health’s mission to transform peritoneal dialysis resonates deeply with me. I see tremendous potential in this approach to improving quality of life for patients.”
Hahn, an experienced financial strategist in the life sciences sector, joins the board with a track record of guiding biotech companies through fundraising and upscaling. In addition to his current role at Verona Pharma, Hahn has held CFO positions at Dova Pharmaceuticals, Cempra and Athenix. “Opterion Health is at a truly exciting inflection point,” said Hahn. “The science is compelling and the opportunity to make a real difference in patients’ lives is profound.”
Chairman David Ebsworth welcomed the appointments, calling them “a major milestone” for the company. “Rice’s leadership in renal care and Mark’s financial expertise bring extraordinary strength to our governance,” he said.
Based near Basel, Switzerland, Opterion Health is developing a PD solution planned to reshape treatment for patients with chronic kidney disease.
Ella Day
25/6/25
Related Content
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National …
Bayer’s cardiovascular drug shows impressive Phase III results
Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events …
